"Impressive" benefits with CV Tech's COLD-fX

12 March 2007

The American Botanical Council, North America's leading non-profit research and education organization on herbal medicines, reviewed clinical data on the health benefits of CVT-E002, the active ingredient in COLD-fX, and found it demonstrated "impressive" benefits.

COLD-fX is a scientifically formulated product made by Toronto, Canada-based CV Technologies that naturally strengthens the body's immune system against cold and flu viruses. It is Canada's number-one selling cold and flu remedy and has been clinically shown to prevent and treat upper respiratory tract infections.

The medical ABC review, which was headed by Bruce Barrett, of the University of Wisconsin, suggests that COLD-fX is effective in helping to prevent the incidence of colds and flu. After assessing both pharmacological and clinical trial data on the agent, the authors wrote that the research on COLD-fX is "impressive" and promising, pointing out that they "found some evidence of preventive efficacy" and "evidence suggesting ability to prevent acute respiratory infection."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight